PharmacoEconomics & Outcomes News 792, p16 - 2 Dec 2017
Lung involvement raises costs for
systemic sclerosis patients
Interstitial lung disease (ILD) and pulmonary arterial
hypertension (PAH) substantially increase healthcare
costs and have poorer survival outcomes for patients
with systemic sclerosis, according to a group of US-
The retrospective cohort analysis
healthcare use and costs (2014 values) from nationwide
claims databases. Data were collected for patients with
newly-diagnosed (incident) systemic sclerosis with or
without ILD and/or PAH, who were continuously
enrolled over a 5-year period.
Of patients with continuous enrolment over a 5-year
period, 1957 had incident systemic sclerosis, 219 had
ILD-related disease and 108 had PAH-related disease.
Average all-cause healthcare costs were substantially
higher for patients with ILD- ($US191 107) and PAH-
related disease ($254 425) over 5 years, compared with
patients with non-lung-involved systemic sclerosis
($101 839). A similar pattern was seen for annual costs,
where they ranged from $31 285 to $55 446 for the ILD
group, $44 454 to $63 320 for the PAH group, and
$18 513 to $23 268 for non-lung-involved disease.
Median survival time was significantly shorter in the ILD
and PAH groups (11.3, 8.8 vs 6.0 years, respectively;
p < 0.001).
"These data highlight that there remains an unmet
need to identify more effective therapeutic strategies for
both ILD and PAH", conclude the authors.
* Funded by Genentech Inc and F. Hoffmann-La Roche.
Fischer A, et al. All-cause Healthcare Costs and Mortality in Patients with
Systemic Sclerosis with Lung Involvement. The Journal of Rheumatology : 15 Nov
PharmacoEconomics & Outcomes News 2 Dec 2017 No. 7921173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved